Clinical Trials

136 enrolled

Prostatic Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 2 FDA

Phase EARLY_PHASE1 Active not recruiting

Ovarian Neoplasms

NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

Glioblastoma, Glioma

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Phase 1/2 Active not recruiting

Metastatic Castration-sensitive Prostate Cancer

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04068753 2026-02-10

STAR

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Uterine Cervical Neoplasms

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

Phase 1/2 Active not recruiting

Glioma

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 enrolled

Tumor-Agnostic

Neoplasms

NCT04170153 2026-01-30

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

161 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT03601923 2026-01-28

Niraparib in Patients With Pancreatic Cancer

Phase 1/2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Breast

Breast Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

20 enrolled

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

30 enrolled

Glioblastoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT03983993 2026-01-05

NIPAVect

26 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT05021562 2025-12-31

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Active not recruiting

354 enrolled

Ovarian Neoplasms

NCT03431350 2025-12-23

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled